Shots:
The US has approved Sarclisa Escena (isatuximab-irfc; SC) + SoC for the treatment of pts with MM across all existing indications of Sarclisa IV formulation
Approval was backed by multiple trials, incl. P-III (IRAKLIA) in R/R MM, which showed shorter treatment time & fewer infusion-related reactions with Sarclisa Escena
In IRAKLIA, SC Sarclisa delivered…
Shots:
The MHLW has approved Sarclisa (isatuximab; SC) + SoC for MM, while regulatory filing for the CirCLIQ on-body injector (OBI), based on the enFuse platform & submitted by Enable Injections, is under review; filing for both OBI & SC manual injection is under FDA review
Approval was based on the P-III (IRAKLIA) study in R/R…
Shots:
Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery.
To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…

